DE69928235D1 - Cyclin-abhängige kinase inhibitoren - Google Patents

Cyclin-abhängige kinase inhibitoren

Info

Publication number
DE69928235D1
DE69928235D1 DE69928235T DE69928235T DE69928235D1 DE 69928235 D1 DE69928235 D1 DE 69928235D1 DE 69928235 T DE69928235 T DE 69928235T DE 69928235 T DE69928235 T DE 69928235T DE 69928235 D1 DE69928235 D1 DE 69928235D1
Authority
DE
Germany
Prior art keywords
cyclin
cdk
kinase inhibitors
dependent kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69928235T
Other languages
English (en)
Other versions
DE69928235T2 (de
Inventor
Roger John Griffin
Alan Hilary Calvert
Nicola Jane Curtin
David Richard Newell
Bernard Thomas Golding
Jane Anne Endicott
Martin Edward Mantyla Noble
Francis Thomas Boyle
Philip John Jewsbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of DE69928235D1 publication Critical patent/DE69928235D1/de
Application granted granted Critical
Publication of DE69928235T2 publication Critical patent/DE69928235T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69928235T 1998-03-28 1999-03-29 Cyclin-abhängige inhibitoren Expired - Fee Related DE69928235T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9806739 1998-03-28
GBGB9806739.0A GB9806739D0 (en) 1998-03-28 1998-03-28 Cyclin dependent kinase inhibitors
PCT/GB1999/000830 WO1999050251A2 (en) 1998-03-28 1999-03-29 Cyclin dependent kinase inhibitors

Publications (2)

Publication Number Publication Date
DE69928235D1 true DE69928235D1 (de) 2005-12-15
DE69928235T2 DE69928235T2 (de) 2006-08-10

Family

ID=10829498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928235T Expired - Fee Related DE69928235T2 (de) 1998-03-28 1999-03-29 Cyclin-abhängige inhibitoren

Country Status (9)

Country Link
EP (1) EP1066266B1 (de)
JP (1) JP2002509921A (de)
AT (1) ATE309223T1 (de)
AU (1) AU753716B2 (de)
CA (1) CA2326357A1 (de)
DE (1) DE69928235T2 (de)
ES (1) ES2253881T3 (de)
GB (1) GB9806739D0 (de)
WO (1) WO1999050251A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253915T1 (de) * 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AU2002312933B2 (en) * 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
KR20120062863A (ko) 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
WO2007036732A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
CA2639888A1 (en) * 2006-02-15 2007-08-23 Basf Se 2-substituted pyrimidines and their use as pesticides
KR20180102590A (ko) 2015-12-24 2018-09-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
CN107118162A (zh) * 2017-04-28 2017-09-01 大连联化化学有限公司 2，4，5‑三氨基‑6‑环已基氧基嘧啶盐酸盐的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1092343B (it) * 1978-02-02 1985-07-06 Poli Ind Chimica Spa Pirimidilsolfuri ad attivita' antisecretoria,processo per la loro preparazione e composizioni farmaceutiche che li contengono
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
EP0540318A1 (de) * 1991-10-30 1993-05-05 Fisons Corporation 2-Heterozyklische Ethylaminderivate und ihre Verwendung als Arzneimittel
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
KR100257129B1 (ko) * 1993-09-11 2000-05-15 성재갑 신규 세팔로스포린계 항생제 및 이의 제조방법
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
JPH09301958A (ja) * 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
AU753716B2 (en) 2002-10-24
AU3155199A (en) 1999-10-18
EP1066266A1 (de) 2001-01-10
JP2002509921A (ja) 2002-04-02
EP1066266B1 (de) 2005-11-09
WO1999050251A2 (en) 1999-10-07
GB9806739D0 (en) 1998-05-27
DE69928235T2 (de) 2006-08-10
CA2326357A1 (en) 1999-10-07
ATE309223T1 (de) 2005-11-15
WO1999050251A3 (en) 2000-02-03
ES2253881T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
DE69928235D1 (de) Cyclin-abhängige kinase inhibitoren
BR0314001A (pt) Pirazolopirimidinas como inibidores de cinase dependente de ciclina
CY1106933T1 (el) Ενωσεις πυριμιδινης
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137888A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
RS94703A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
BG104996A (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
WO2002079193A8 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
LU91657I2 (fr) Tocéranibe et ses dérivés pharmaceutiquement acceptables (PALLADIA®)
HK1112233A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
NO971038L (no) Pyrimido£5,4-d|pyrimidiner, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling av dem
WO1999006540A3 (en) Inhibitors of cell-cycle progression and uses related thereto
NO20006027L (no) Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
IL161092A0 (en) N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
TR200101860T2 (tr) Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
DE60028253D1 (de) Neue purine
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee